Compare RTX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | SNY |
|---|---|---|
| Founded | 1934 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.1B | 107.3B |
| IPO Year | 1994 | N/A |
| Metric | RTX | SNY |
|---|---|---|
| Price | $203.52 | $47.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $196.17 | $58.00 |
| AVG Volume (30 Days) | ★ 4.0M | 3.0M |
| Earning Date | 04-21-2026 | 04-23-2026 |
| Dividend Yield | 1.37% | ★ 3.41% |
| EPS Growth | ★ 39.72 | N/A |
| EPS | ★ 4.96 | N/A |
| Revenue | ★ $80,738,000,000.00 | N/A |
| Revenue This Year | $6.41 | $3.86 |
| Revenue Next Year | $6.65 | $5.64 |
| P/E Ratio | $39.81 | ★ $6.14 |
| Revenue Growth | ★ 17.15 | N/A |
| 52 Week Low | $112.63 | $43.32 |
| 52 Week High | $214.50 | $55.73 |
| Indicator | RTX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 56.08 |
| Support Level | $193.07 | $46.88 |
| Resistance Level | $205.41 | $48.88 |
| Average True Range (ATR) | 4.44 | 0.76 |
| MACD | 0.62 | 0.26 |
| Stochastic Oscillator | 98.46 | 72.03 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.